Page 5 - Biocon

Biocon's insulin biosimilar Glargine gets preference in top US formulary

The USFDA had approved biosimilar Insulin Glargine-yfgn injection (Semglee) as the first interchangeable biosimilar product in July this year

Stocks to Watch: Asian Paints, Biocon, IDBI, JSW Steel, Lodha, TVS Motors

State-run PSU banks and telecom stocks are likely to be in focus along with a slew of mid- and small-cap companies that shall announce their September earnings today

Pandora Papers: 'Kunal Kashyap has no influence over Biocon-linked trust'

According to a company statement, the Deanstone Trust, which was mentioned as part of a leak of offshore tax haven files called the 'Pandora Papers,' was set up for philanthropic endeavours

Decoded: Of 'Pandora Papers', insider trading and Biocon link

Kiran Mazumdar-Shaw, executive chairperson of Biocon denied any impropriety

Allegro Capital named in Pandora Papers: What was the Sebi order about?

Kunal Kashyap's Sebi order was also linked to Biocon. It was related to a 2018 announcement about Biocon's global collaboration with Sandoz

Stocks to watch: ZEEL, Info Edge, NBCC, Biocon, United Breweries, SJVN

State-owned power giant NTPC has bagged 1.9 GW solar projects in CPSU Scheme-II tender

Biocon Biologics, Serum Institute Life Sciences enter strategic alliance

Work on mRNA platform, antibodies for dengue, HIV in the plan

Sensex tanks 720 pts from day's high, ends 125 pts down; Nifty PSB drops 3%

On the weekly basis, the benchmark indices gained, thus taking their winning run to the fourth straight week

Stocks to watch: Biocon, Hero Moto, Poonawalla Fin, TVS Motor, bank stocks

Hero MotoCorp on Thursday said it will increase the price of its entire model range by up to Rs 3,000 from September 20

Biocon Biologics to offer 15% stake to Serum Institute Life Sciences

Biocon Biologics, a subsidiary of Biocon, on Thursday said it will offer around 15 per cent stake to Serum Institute Life Sciences at a post-money valuation of about $4.9 billion

SAT stays Biocon insider trading order

Sebi had directed Allegro Capital and its owner Kunal Kashyap to disgorge Rs 25 lakh for allegedly dealing in shares of Biocon while in possession of price sensitive information.

Top headlines: India sticks to growth forecast; Kerala struggles with Covid

Business Standard brings to you the top headlines on Friday

USFDA okays Biocon insulin Semglee as first interchangeable biosimilar drug

Semglee may now be substituted for Sanofi's Lantus by a pharmacist in the US

Coronavirus LIVE: 22k new cases in Kerala in a day; 6,258 in Maharashtra

India recorded 29,689 new coronavirus infections on Tuesday, which pushed its tally of Covid-19 cases to 31,440,951

Biocon partners Adagio for licence to make Covid-19 antibody cocktail

Treatment claims to address the resistant Delta variant as well

Biocon Biologics gets licence from Adagio for antibody Covid treatment

Initial data indicate that ADG20 could provide both rapid and durable protection against Covid-19 for up to one year

Biocon likely to seek full marketing authorisation for Covid-19 drug

Expects results from phase 4 study of itolizumab by end of this quarter

Biocon Q1 net profit declines 35% to Rs 108.4 cr; revenue at Rs 1807.8 cr

Biotechnology major Biocon has reported a 35.39 per cent decline in its consolidated net profit at Rs 108.4 crore for the quarter ended June 30, 2021 mainly on account of its share of loss in associate startup entity Bicara Therapeutics Inc. The company had posted a net profit of Rs 167.8 crore for the corresponding period of the previous fiscal, Biocon said in a late night filing on Thursday. Consolidated revenue of the company stood at Rs 1,807.8 crore for the quarter under consideration. It was Rs 1,712.1 crore for the same period a year ago, it added. "Consolidated revenues, at Rs 1,808 crore, saw a muted growth on account of COVID-related operational challenges at Biocon's API facilities, both in Bengaluru and Hyderabad," Biocon Executive Chairperson Kiran Mazumdar-Shaw said. Q1FY22 P&L was also impacted by a share of loss in its Boston-based associate start-up entity, Bicara Therapeutics Inc, she added. "The outlook for the rest of the year is promising with several drug ...

Stocks to watch: Zomato, RIL, SBI Card, Voda Idea, Airtel, BPCL, Biocon

Forty-one companies, including RIL, JSW Steel, SBI Card, YES Bank and Federal Bank will report their quarterly numbers today

Top headlines: Parliament meets, firms face heat on independent valuation

Here are the top headlines on Monday morning